

P/S Support

Supports Healthy Adrenal Function



Biogenetix
Nutrition Uncompromised

PRODUCT BENEFITS*

- Supports proper adrenal function
- Supports the body's ability to protect against oxidative damage
- Supports healthy moods
- Supports memory and cognition

P/S Support is a phospholipid formulation that can be useful in support of the HPA Axis, memory and cognition, healthy moods, normal cortisol levels, and protects against oxidative damage. It may also be helpful in supporting healthy blood sugar metabolism.



SUPPLEMENT FACTS

	Amount Per Serving	% Daily Value
Serving size: 2 Capsules Servings per container: 30		
Phosphatidylserine	420 mg	**

* Percent Daily Values are based on a 2000 calorie diet.

** Daily Value Not Established

Other Ingredients: Gelatin (Capsule), Microcrystalline Cellulose, Magnesium Stearate.

DIRECTIONS FOR USE

Take 2 capsules once per day, or as directed by your health care professional.

STORAGE

Store in a cool, dry place away from direct sunlight. Product from unopened containers that have been stored under recommended conditions (55-85° F / 13-29° C) may be used for up to 36 months.

WARNING

Consult your health care professional before use if pregnant, nursing, taking medications, or for any use by minors. Do not use if safety seal is broken or missing. Keep out of reach of children.

*To be provided by health care professionals only. The dosage recommendations are only for your health care provider's consideration. Please consult your health care provider for your individual dosing instructions. This product is for nutritional purposes only. It is not designed to diagnose, treat, reverse, cure, or prevent any disease. This product is not intended to replace or delay the use of prescription medication. These statements have not been evaluated by the FDA. All rights reserved © Biogenetix, LLC

www.biogenetix.com
orders@biogenetix.com
(833) 525-0001

REFERENCE LIST

1. Ameducci L, Crook TH, Lippi A, et al. Use of phosphatidylserine in Alzheimer's Disease. *Ann Ny Acad Sci* 1991 ;640:245-249.
2. Bergh, F.T., et al. Dysregulation of the hypothalamo-pituitary- adrenal axis is related to the clinical course of MS. *Neurology* 53; 772-777,1999.
3. Brambilla F, Maggioni M, Panerai AE, et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients effects on phosphatidylserine therapy. *Neuropsychobiology* 1996;34:18-21.
4. Brambilli F, Magioni M. Blood levels of cytokines in elderly patients with major depressive disorder. *Acta Psychiatr Scand* 1998;97: 309-313.
5. Brindly DN. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in metabolic syndrome. *Int J Obes Relat Metab Disord* 1995;19(Suppl 1):S69-75.
6. Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: A double-blind, placebo controlled multicenter study on efficacy of phosphatidylserine administration. *Aging Clin Exp Res* 1993;5:123-133.
7. Cenacchi T, Bertoldin R, Farina C, et al. Cognitive decline in the elderly. A double blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. *Aging* 1993;5:123-133.
8. Crook TH, Petrie W, Wells C, Massari DC, Effects of phosphatidylserine in Alzheimer's Disease. *Psychopharmacol Bull* 1992;28:61-66.
9. Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. *Neurology* 1991 ;41 :644-649.
10. Cunningham-Rundies, C., et al. *Proc. Nat Acada. Sci USA.* 75:3387, 1978.
11. Daynes, R., et al. *Eur J Immunol.* 20:793, 1990.
12. Fahey TD, Pearl MS. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. *Biol Sport* 1998;15:135-144.
13. Freidman JM. Leptin, leptin receptors, and the control of body weight. *Nutr Rev.* 1998;56(2):S38-S46.
14. Guhad, FA, et al. Salivary IgA as a marker of social stress in rats. *Neurosci Lett,* 216(2). 137-140,1996.
15. Havel PJ. Leptin production and action: relevance to energy balance in humans. *Am J Clin Nutr.* 1998;67(3):355-358.
16. Kidd PM, Phosphatidylserine; membrane nutrient for memory. A clinical and mechanistic assessment. *Altern Med Rev* 1996;1:70-84.
17. Latorraca S, Piersanti P, Tesco G, et al. Effects of phosphatidylserine on free radical susceptibility in human diploid fibroblasts. *Neurol Transm Park Dis Dement Sect* 1993;6:73-77.
18. LoPresti, JS and Nicoloff, JT. Thyroid response to critical illness. *Endocrinology of Critical Disease.* Human Press. Totowa. NJ. 1997. pp 157- 173.
19. Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. *Acta Psychiatr Scand* 1990;81 :265-270.
20. Maggioni M, Picotti GM, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. *Acta Psychiatr Scan* 1990;81 :265-270.
21. Monteleone P, Beintat L, Tanzillo C, et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. *Neuroendocrinology* 1990;52:243-248.
22. Monteleone P, Mag M, Beinat, et al. Blunting of chronic phosphatidylserine administration of the stress-induced activation of the hypothalamic-pituitary-adrenal axis in healthy men. *Eur J Clin Pharmacol* 1992;41 :385- 388.
23. Nerozzi D, Aceti F, Melia E, et al. Early cortisol escape phenomenon reversed by phosphatidylserine in elderly normal subjects. *Clinical Trial J* 1989;26:33-38.
24. Palmieri G. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. *Clin Trials J* 1987;24:73-83.
25. Scott, H., et al. *Scan. J. Gastroenterol.* 15:81, 1980.
26. Stockigt, JR. Update on the Sick Euthyroid Syndrome, in Baverman, LE ed., *Diseases of the Thyroid,* Humana Press, Totowa, NJ, 1997, pp. 49-68.
27. Strakis, CA and Chrousos, GP. Neuroendocrinology and Pathophysiology of the Stress System, *Ann Ny Acad Sci,* Vol. 771, pp. 1-18,1995.
28. Van Der Pomp G., et al. Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer. *Psychoneuroendocrinology,* 21(4). 361- 374,1996.